UP!

MED $33.57

MED target price
33.57
0
0
Medifast, Inc.
Type
Public
Traded as NYSE: MED
S&P 600 Component
Industry Weight loss
Founded 1980
Headquarters Owings Mills, Maryland, United States
Key people
Daniel R. Chard, CEO
Products Medifast diet
Revenue Decrease US$ 285.3 million (2014)
Operating income
Decrease US$ 30.2 million (2014)
Net income
Decrease US$ 13.2 million (2014)
Total assets Decrease US$ 115.9 million (2014)
Total equity Decrease US$ 80.5 million (2014)
Number of employees
808 (2014)
Website www.medifast1.com

Medifast, Inc. is an American nutrition and weight loss company based in Owings Mills, Maryland. The company owns five subsidiaries: Jason Pharmaceuticals, Inc. (Jason), Take Shape for Life, Inc. (TSFL), Jason Enterprises, Inc., Jason Properties, LLC and Seven Crondall, LLC. Medifast produces, distributes, and sells weight loss and other health-related products through websites, multi-level marketing, telemarketing, franchised weight loss clinics, and medical professionals.

The company is public with a market capitalization of $405 million, as of October 2014.

Medifast was founded in 1980 by William Vitale, a medical doctor. His products were sold directly to other doctors, who in turn prescribed them to their patients.

The company is publicly traded on the New York Stock Exchange (symbol: MED).

On July 17, 1995, HealthRite (predecessor of Medifast) changed its name from Vitamin Specialties Corp.

In October 2010, Medifast was ranked number 1 on Forbes magazine's list of "America's 100 Best Small Companies". The company was ranked 18th as of the 2014 list.

In September 2012, Medifast's subsidiary, Jason Pharmaceuticals, paid a $3.7 million USD civil penalty for false advertising. The Federal Trade Commission and United States Department of Justice said that advertisements for the "Medifast 5 & 1 Plan" low-calorie diet told consumers they could "lose up to 2-5 pounds per week.", and that these weight-loss claims lacked a reasonable scientific basis, and were unsubstantiated. Under the settlement, any future claims made by the company must be backed by at least one human clinical study.

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q3 2022 2022-11-02 Future report Set alerts
Q2 2022 2022-08-03 3.42 3.42
Q1 2022 2022-05-02 3.59 3.59
Q4 2021 2022-02-23 2.91 2.91
Q3 2021 2021-11-04 0.00 0.00
Q2 2021 2021-08-04 3.96 3.96
Q1 2021 2021-05-04 3.46 3.46
Q4 2020 2021-02-25 2.36 2.36
Q3 2020 2020-11-02 2.91 2.91
Q2 2020 2020-08-05 1.96 1.86

Ratings

2016-01-29 Initiated Coverage Wunderlich Hold to Hold $32.00
2016-01-11 Upgrade Sidoti Neutral to Buy $35.00
2015-11-30 Downgrade Sidoti Buy to Neutral
2015-11-08 Reiterated Rating Canaccord Genuity Hold $33.00
2015-10-15 Reiterated Rating Canaccord Genuity Hold $31.00
2015-10-05 Upgrade Sidoti Neutral to Buy $33.00
2015-05-08 Initiated Coverage Canaccord Genuity Hold $34.00
2015-03-15 Reiterated Rating Canaccord Genuity Hold $33.00
2014-11-07 Downgrade Imperial Capital Outperform to In-Line $34.00 to $32.00
2014-11-06 Reiterated Rating Canaccord Genuity Hold $29.00 to $30.00
2014-08-29 Boost Price Target Wedbush Outperform $32.00 to $36.00
2014-08-08 Lower Price Target Canaccord Genuity $32.00 to $29.00
2014-08-08 Lower Price Target Wedbush $37.00 to $32.00
2014-08-08 Lower Price Target Imperial Capital Outperform $36.00 to $34.00
2014-06-12 Boost Price Target Canaccord Genuity Hold $31.00 to $32.00
2014-05-06 Lower Price Target Canaccord Genuity $32.00 to $31.00
2014-04-23 Boost Price Target Imperial Capital Outperform $30.00 to $36.00
2014-03-13 Reiterated Rating Imperial Capital Buy
2013-11-06 Lower Price Target Wedbush Outperform $35.00 to $30.00
2013-11-06 Lower Price Target Janney Montgomery Scott Neutral $27.00 to $25.00
2013-11-06 Lower Price Target Canaccord Genuity Hold $30.00 to $27.00
2012-11-06 Reiterated Northland Securities Outperform $29 to $34
2012-01-30 Initiated Standpoint Research Buy $24
2011-11-07 Downgrade Canaccord Genuity Buy to Hold
2011-06-21 Reiterated Northland Securities Outperform $29 to $32
2011-04-01 Reiterated Northland Securities Outperform $44 to $29
2010-08-05 Reiterated Northland Securities Outperform $37 to $44
2010-05-06 Reiterated Northland Securities Outperform $35 to $37
2008-08-13 Initiated Northland Securities Outperform $10
2008-03-17 Reiterated Canaccord Adams Hold $5 to $4.50
2007-11-09 Reiterated Canaccord Adams Hold $7 to $5
2007-03-22 Initiated First Albany Neutral
2007-01-19 Initiated BB&T Capital Mkts Buy $16
2016-01-29 Initiated Coverage Wunderlich Hold to Hold $32.00
2016-01-11 Upgrade Sidoti Neutral to Buy $35.00
2015-11-30 Downgrade Sidoti Buy to Neutral
2015-11-08 Reiterated Rating Canaccord Genuity Hold $33.00
2015-10-15 Reiterated Rating Canaccord Genuity Hold $31.00

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
ModusLink Global Solutions Inc 9.38%  (1194891) MED /
MACDONALD BRADLEY T 4.55%  (579521) MED /
SHEETZ GUY Executive Vice President 3.22%  (410430) MED /
MCDEVITT MICHAEL S Chief Executive Officer 2.67%  (340012) MED /
SHEETZ MARGARET MACDONALD President and COO 2.57%  (327346) MED /
MACDONALD MICHAEL C 2.47%  (314188) MED /
CONNORS BRENDAN VP Finance 0.72%  (91484) MED /
LAW RICHARD J Corporate Secretary 0.49%  (62081) MED /
CONNOLLY CHARLES P 0.32%  (41374) MED /
LAVIN GEORGE 0.19%  (24785) MED /
ROBINSON TIMOTHY G Chief Financial Officer 0.19%  (24708) MED /
Welling Glenn W. 0.18%  (22380) HAIN / JMBA / MED / ROVI /
GROVES JASON L 0.17%  (21697) MED /
MILLS JEANNETTE M 0.16%  (20116) MED /
MCDANIEL JOHN P 0.14%  (18289) FMAR / MED / WRE /
BROWN JEFFREY J 0.14%  (18135) MED / OUTR / RCAP / RCII /
MAGUIRE CATHERINE T 0.12%  (15074) MED /
WILLIAMS LEO Executive Vice President 0.12%  (15000) MED /
BONDROFF BARRY B 0.11%  (14533) FMAR / MED /
Chard Daniel R Chief Executive Officer 0.11%  (13920) MED / NUS /
SASSANO CARL E 0.10%  (12820) IEC / MED / TRNS /
TRAVIS MARY T Former Board member 0.10%  (12583) MED /
AMELI MEHRNAZ MONA President 0.08%  (10809) MED /
HARTWIG JORGENE K. 0.08%  (9808) MED /
BYRNES KEVIN G 0.07%  (9375) BYBK / MED /
REECE JERRY D 0.07%  (8792) MED /
BARNUM HARVEY C JR 0.07%  (8742) MED /
HALLQUIST CONSTANCE J. 0.06%  (7373) MED /
SCHLACKMAN SCOTT 0.05%  (7001) MED /
GOULD DONALD Executive Vice President 0.05%  (6804) MED /
UPHOUSE JEANNE M Executive Vice President 0.03%  (3804) MED /
VIETRI DOMINICK Executive Vice President 0.03%  (3804) MED /
KAGEN BRIAN Executive Vice President 0.03%  (3804) MED /
LLOYD BRIAN Executive Vice President 0.01%  (1865) MED /